Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Amivantamab and lazertinib plus platinum-pemetrexed chemotherapy versus platinum-pemetrexed after osimertinib failure in EGFR-mutated advanced non-small cell lung cancer
NL-OMON60689Phase 3Active, not recruiting
- Sponsor
- Janssen Pharmaceutical
- Start
- Jan 2022
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of amivantamab, lazertinib, carboplatin and pemetrexed in non-small cell lung cancer (NSCLC), sponsored by Janssen Pharmaceutical. Started Jan 2022; status: active, not recruiting.
02
Drugs
amivantamablazertinibcarboplatinpemetrexed
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NL-OMON60689.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60689.